RxDoctor Payments Data

Amanda Daggett, MD

Dermatology · Ridgeland, MSNPI 1457706434

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. LEO Pharma Inc. accounts for 72.2% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $10,114 and has fallen 68.5% since, to $3,187 in 2025.

$24,565in general payments, 2019–2025

Across 510 payments — averaging $48.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$18K
  • AbbVie$1K
  • UCB, Inc.$866
  • Johnson & Johnson$785
  • Novartis$486
  • Sanofi$397
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$6,28726%
  • Speaking & faculty fees$10,64443%
  • Food & beverage$7,38330%
  • Education$2511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,565 in reported general payments places this provider in the 85th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$117,612
Medicare patients
405
Services billed
1,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab34$128,603
OpzeluraRuxolitinib Phosphate12$23,861
Clobetasol Propionate93$5,404
Tacrolimus34$2,840
Fluorouracil36$2,646
Minoxidil416$2,458
Calcipotriene19$1,712
Ketoconazole114$1,702
Triamcinolone Acetonide98$1,255
Tretinoin25$1,215
Econazole Nitrate20$1,212
Fluocinolone AcetonideFluocinolone/Shower Cap27$1,195
Clindamycin Phosphate13$605
Hydroxychloroquine Sulfate11$349
Hydrocortisone39$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$240$23,86112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Ridgeland

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →